The APAC epirubicin market is expected to grow from US$ 29,679.40 thousand in 2022 to US$ 37,447.28 thousand by 2028; it is estimated to grow at a CAGR of 4.0% from 2022 to 2028.
Epirubicin is an anthracycline drug that is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy. Further, the number of people diagnosed with liver cancer has been rising, and it is common in several parts of the region. Hence, the rising prevalence of cancer cases is driving the epirubicin market across the region.
Epirubicin is an anthracycline drug that is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy. Further, the number of people diagnosed with liver cancer has been rising, and it is common in several parts of the region. Hence, the rising prevalence of cancer cases is driving the epirubicin market across the region.
Market Overview
The APAC epirubicin market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. The developing economies such as China, India, and Indonesia are investing substantially in infrastructure and industrial development. In APAC, China is the largest market for epirubicin. The market growth is primarily attributed to the growing pharmaceutical industry, increasing developments by the market players, and favorable regulatory policies. Further, the excessive population in China and the rising prevalence of cancer are majorly boosting the demand for cancer drugs. Also, the growing prevalence of cancer in China is likely to increase the demand for cancer treatment. As per the WHO report, in 2020, there were ~4,568,754 new cases of cancer and 3,002,899 cancer-associated deaths in China. Thus, the huge cancer patient population and product and treatment developments by the market players are expected to propel the demand for cancer vaccines in the country.APAC Epirubicin Market Segmentation
The APAC epirubicin market is segmented based on dosage, application, distribution channel, and country- Based on dosage, the APAC epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022.
- Based on distribution channel, the APAC epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022.
- Based on country, the APAC epirubicin market is categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC. Further, China dominated the market in 2022. Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Miracalus Pharma Pvt. Ltd., Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the APAC epirubicin market.
Table of Contents
1. Introduction
3. Research Methodology
4. APAC Epirubicin Market - Market Landscape
5. APAC Epirubicin Market- Key Market Dynamics
6. Epirubicin Market- APAC Analysis
7. APAC Epirubicin Market Analysis - By Dosage
8. APAC Epirubicin Market Analysis - By Application
9. APAC Epirubicin Market Analysis - By Distribution Channel
10. APAC Epirubicin Market - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Miracalus Pharma Pvt. Ltd.
- Mylan N.V.
- Pfizer Inc.
- Salius Pharma Pvt Ltd
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | October 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 29679.4 Million |
| Forecasted Market Value ( USD | $ 37447.28 Million |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 7 |
